PRESTIGE CONSUMER HEALTHCARE INC. Financials Prestige Consumer Healthcare Inc. Deutsche Boerse AG
Equities
PBV
US74112D1019
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59 EUR | -0.84% |
|
-1.67% | +6.31% |
| 05-15 | Sector Update: Health Care Stocks Rise Pre-Bell Wednesday | MT |
| 05-15 | Transcript : Prestige Consumer Healthcare Inc., Q4 2024 Earnings Call, May 15, 2024 |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,844 | 2,198 | 2,658 | 3,112 | 3,603 | 3,207 | - | - |
| Enterprise Value (EV) 1 | 1,844 | 2,198 | 2,658 | 3,112 | 4,682 | 3,207 | 3,207 | 3,207 |
| P/E ratio | 13.2 x | 13.6 x | 13.1 x | -38 x | 17.4 x | 14.6 x | 13.7 x | 13.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.91 x | 2.33 x | 2.45 x | 2.76 x | 3.2 x | 2.84 x | 2.77 x | 2.71 x |
| EV / Revenue | 1.91 x | 2.33 x | 2.45 x | 2.76 x | 3.2 x | 2.84 x | 2.77 x | 2.71 x |
| EV / EBITDA | 5.62 x | 6.68 x | 7.23 x | 8.23 x | 9.64 x | 8.53 x | 8.36 x | 8.12 x |
| EV / FCF | 9.1 x | 10.3 x | 10.6 x | 14 x | 15 x | 12.6 x | 11.9 x | - |
| FCF Yield | 11% | 9.71% | 9.42% | 7.13% | 6.64% | 7.91% | 8.43% | - |
| Price to Book | 1.59 x | 1.62 x | 1.69 x | 2.15 x | 2.18 x | 1.55 x | - | - |
| Nbr of stocks (in thousands) | 50,266 | 49,865 | 50,199 | 49,688 | 49,649 | 49,915 | - | - |
| Reference price 2 | 36.68 | 44.08 | 52.94 | 62.63 | 72.56 | 64.25 | 64.25 | 64.25 |
| Announcement Date | 07/05/20 | 06/05/21 | 05/05/22 | 04/05/23 | 14/05/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 963 | 943.4 | 1,087 | 1,128 | 1,125 | 1,129 | 1,157 | 1,185 |
| EBITDA 1 | 328.1 | 328.9 | 367.7 | 378.1 | 373.9 | 375.9 | 383.8 | 395 |
| EBIT 1 | 299.1 | 298.8 | 326.7 | 347.8 | 342.4 | 342.6 | 353.1 | 364 |
| Operating Margin | 31.06% | 31.67% | 30.06% | 30.84% | 30.43% | 30.35% | 30.52% | 30.72% |
| Earnings before Tax (EBT) 1 | 191.2 | 204.1 | 262.5 | -93.92 | 276 | 289.3 | 309.3 | - |
| Net income 1 | 142.3 | 164.7 | 205.4 | -82.31 | 209.3 | 220.2 | 234.6 | 236 |
| Net margin | 14.77% | 17.46% | 18.9% | -7.3% | 18.6% | 19.51% | 20.27% | 19.92% |
| EPS 2 | 2.780 | 3.250 | 4.040 | -1.650 | 4.170 | 4.392 | 4.697 | 4.780 |
| Free Cash Flow 1 | 202.6 | 213.4 | 250.3 | 221.9 | 239.4 | 253.7 | 270.4 | - |
| FCF margin | 21.03% | 22.62% | 23.03% | 19.68% | 21.27% | 22.47% | 23.37% | - |
| FCF Conversion (EBITDA) | 61.74% | 64.87% | 68.08% | 58.7% | 64.03% | 67.49% | 70.45% | - |
| FCF Conversion (Net income) | 142.37% | 129.56% | 121.86% | - | 114.35% | 115.21% | 115.29% | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 07/05/20 | 06/05/21 | 05/05/22 | 04/05/23 | 14/05/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2026 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 274.5 | 266.9 | 277.1 | 289.3 | 275.5 | 285.9 | 279.3 | 286.3 | 282.7 | 277 | 260.6 | 282.3 | 293.2 | 292.6 | 275.4 |
| EBITDA 1 | 90.47 | 85.42 | 94.57 | 91.82 | 94.16 | 97.53 | 93.98 | 95.66 | 93.8 | 90.42 | 79.77 | 94.97 | 100.2 | 100.9 | 94.4 |
| EBIT 1 | 82.42 | 76.94 | 86.19 | 83.57 | 86.03 | 89.22 | 85.19 | 88.25 | 86.83 | 82.15 | 71.54 | 86.26 | 91.95 | 92.65 | 82.43 |
| Operating Margin | 30.03% | 28.82% | 31.11% | 28.89% | 31.23% | 31.21% | 30.5% | 30.82% | 30.71% | 29.66% | 27.46% | 30.56% | 31.36% | 31.66% | 29.93% |
| Earnings before Tax (EBT) 1 | 65.49 | 60.96 | 70.9 | 66.59 | 68.12 | -299.5 | 68.71 | 70.42 | 69.58 | 67.32 | 56.81 | 72.1 | 79.1 | 81.28 | 71.14 |
| Net income 1 | 50.22 | 52.09 | 55.27 | 51.02 | 51.95 | -240.6 | 53.28 | 53.56 | 53.05 | 49.46 | 43.27 | 54.92 | 60.3 | 61.94 | 54.17 |
| Net margin | 18.3% | 19.51% | 19.95% | 17.64% | 18.86% | -84.15% | 19.07% | 18.71% | 18.76% | 17.86% | 16.61% | 19.46% | 20.57% | 21.17% | 19.67% |
| EPS 2 | 0.9900 | 1.020 | 1.090 | 1.020 | 1.040 | -4.830 | 1.060 | 1.070 | 1.060 | 0.9800 | 0.8600 | 1.104 | 1.198 | 1.232 | 1.090 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 03/02/22 | 05/05/22 | 04/08/22 | 03/11/22 | 02/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 08/02/24 | 14/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | 1,079 | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | 2.887 x | - | - | - |
| Free Cash Flow 1 | 203 | 213 | 250 | 222 | 239 | 254 | 270 | - |
| ROE (net income / shareholders' equity) | 13.4% | 13% | 14.1% | 14% | 13.5% | 12.3% | 11.8% | 10.5% |
| ROA (Net income/ Total Assets) | - | - | - | - | 6.28% | 6.2% | 6.1% | 6% |
| Assets 1 | - | - | - | - | 3,336 | 3,552 | 3,845 | 3,933 |
| Book Value Per Share 2 | 23.10 | 27.20 | 31.40 | 29.10 | 33.20 | 41.40 | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 14.6 | 22.2 | 9.64 | 7.78 | 9.55 | 11.6 | 13.7 | 11.9 |
| Capex / Sales | 1.51% | 2.36% | 0.89% | 0.69% | 0.85% | 1.03% | 1.18% | 1% |
| Announcement Date | 07/05/20 | 06/05/21 | 05/05/22 | 04/05/23 | 14/05/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
64.25
USD
Average target price
73.5
USD
Spread / Average Target
+14.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.85% | 791B | |
| +40.45% | 630B | |
| +17.05% | 328B | |
| +9.19% | 298B | |
| +17.25% | 246B | |
| +0.41% | 225B | |
| +10.22% | 218B | |
| +4.41% | 160B | |
| -6.46% | 156B |
- Stock Market
- Equities
- PBH Stock
- PBV Stock
- Financials Prestige Consumer Healthcare Inc.